Please use this link to access this publication. Abstract Introduction A clinical trial of Epidiolex®, the only US FDA-approved cannabis-derived consumer product (CDP), discovered an interaction with an immunosuppressant (tacrolimus)…
Condition: Drug Interactions
Drug interactions in a sample of inpatients diagnosed with cannabis use disorder
Abstract The majority of patients with cannabis use disorder (CUD) regularly take medication. Cannabinoids influence metabolism of some commonly prescribed drugs. However, little is known about the characteristics and frequency…
Drug Interactions in People on Cannabidiol: Is There Cause for Concern?
Abstract Introduction: Cannabidiol (CBD) exhibits multiple therapeutic properties, but its use in advanced cancer patients raises concerns about potential drug–drug interactions (DDIs) due to polypharmacy. This study aims to look for…
Evaluation of potential drug–drug interactions with medical cannabis
Abstract Cannabis–drug interactions have caused significant concerns, mainly due to their role in the cytochrome P450 (CYP) enzyme-mediated metabolic pathway of numerous medications. A systematic review was conducted to gain…
The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications
Please use this link to access this publication. Abstract Purpose Increased cannabis use and recent drug approvals pose new challenges for avoiding drug interactions between cannabis products and conventional medications….
Phytochemical Comparison of Medicinal Cannabis Extracts and Study of Their CYP-Mediated Interactions with Coumarinic Oral Anticoagulants
Abstract Introduction: Treatment with cannabis extracts for a variety of diseases has gained popularity. However, differences in herb-drug interaction potential of extracts from different plant sources are poorly understood. In this…
Drug-drug interactions as a result of co-administering Δ9-THC and CBD with other psychotropic agents
Please use this link to access this publication. ABSTRACT Introduction: To determine, via narrative, non-systematic review of pre-clinical and clinical studies, whether the effect of cannabis on hepatic biotransformation pathways…
Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions
Abstract Objective Cannabidiol (CBD) has been approved by the US Food and Drug Administration (FDA) to treat intractable childhood epilepsies, such as Dravet syndrome and Lennox-Gastaut syndrome. However, the intrinsic…
Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus
Abstract Cannabidiol (CBD), a major purified nonpsychoactive component of cannabis with anticonvulsant properties, was approved by the U.S. Food and Drug Administration (FDA) in June 2018 as an adjuvant treatment…
Chronic nicotine exposure attenuates the effects of Δ9-tetrahydrocannabinol on anxiety-related behavior and social interaction in adult male and female rats
Abstract Introduction Anxiogenic and anxiolytic effects of cannabinoids are mediated by different mechanisms, including neural signaling via cannabinoid receptors (CBRs) and nicotinic cholinergic receptors (nAChRs). This study examined the effects…